يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Juan C. Alcedo"', وقت الاستعلام: 0.84s تنقيح النتائج
  1. 1
    Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

    المؤلفون: Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen, Catarina Pulido, Ana Cvetanovic, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, Ari Alexandrou, Peter Trask, Judy Fredriksson, Zuzana Machackova, Ljiljana Stamatovic, Ernesto Korbenfeld, Jorge Nadal, Helio Pinczowski, Felipe J. Cruz, Gustavo Sousa, Aline C. Goncalves, Gisah Guilgen, Antti Jekunen, Winne Yeo, Chi K. Cheng, Hikmat A. Razeq, Fadi Karak, Fadi Farhat, Servando C. Huerta, Brizio M. Jaime, Juan Feregrino, Omar Castillo-Fernandez, Juan C. Alcedo, Maria Dionisio, Salha Bujassoum, Hatoon Bakhraibah, Alvaro R. Lescure, Camilla Wendt, Sara Margolin, Helena G. Björneklett, Michelina Cairo, Shaker Dakhil, Nguyet Le-Lindqwister, Ling Ma, Kristi J. McIntyre, Joyce O’Shaughnessy, Svetislava J. Vukelja, Donald Richards, John Wallmark

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Receptor, ErbB-2, Phases of clinical research, Gastroenterology, Subcutaneous injection, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Infusions, Intravenous, Adjuvant, Early breast cancer, Aged, 80 and over, Patient preference, Cross-Over Studies, Subcutaneous, Patient Preference, Fixed dose, Middle Aged, Neoadjuvant Therapy, Drug Combinations, Oncology, Chemotherapy, Adjuvant, Patient Satisfaction, 030220 oncology & carcinogenesis, Female, Pertuzumab, medicine.drug, Adult, Quality of life, medicine.medical_specialty, Injections, Subcutaneous, Fixed-dose combination, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, Healthcare resource, Internal medicine, medicine, Humans, Adverse effect, Aged, Neoplasm Staging, Patient-reported outcomes, business.industry, Confidence interval, 030104 developmental biology, business

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa4c6a666e370a233289e49fa120291
    https://zenodo.org/record/5196150

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  2. 2
    Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix

    المؤلفون: Pittayapoom Pattaranutaporn, Mauro Orlando, Firuza Patel, J. J. Zarba, Shahid Hameed, Helen Barraclough, Juan C. Alcedo, Semir Beslija, Luis Casanova, Julie M. Blair, Alfonso Dueñas-González

    المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(13)

    مصطلحات موضوعية: Adult, Cancer Research, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Brachytherapy, Urology, Uterine Cervical Neoplasms, Antimetabolite, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cisplatin, Cervical cancer, Chemotherapy, business.industry, Infant, Newborn, Infant, medicine.disease, Combined Modality Therapy, Gemcitabine, Surgery, Radiation therapy, Oncology, Chemotherapy, Adjuvant, Female, business, Chemoradiotherapy, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f411f3372ce675040f7bcf0fd8f70c
    https://pubmed.ncbi.nlm.nih.gov/21444860

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء